Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged between 18 and 75 years old
• People whose general health and ability to carry out daily activities meets a minimum standard (known as a KPS score of 70 or above — confirm with trial site if unsure what this means)
• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) according to specific international diagnostic guidelines, and whose cancer falls into a particular stage category (BCLC A, B, or C — the trial site can confirm which stage applies)
• People who have at least one liver tumour that can be clearly and accurately measured using scans or imaging
• People whose cancer has been assessed by a panel of liver surgery specialists and agreed to be not suitable for surgical removal
• People who either have no liver scarring (cirrhosis), or whose liver scarring is mild and falls into a specific health classification (Child-Pugh class A)
• People whose recent blood test results meet all of the following levels: platelets at least 75,000/μL; haemoglobin at least 8.5 g/dL; total bilirubin no higher than 30 mmol/L; serum albumin at least 32 g/L; certain liver enzyme levels no more than 6 times the upper limit of normal; kidney function marker (creatinine) no more than 1.5 times the upper limit of normal; blood clotting measures within acceptable ranges; and neutrophil count above 1,500/mm³ (confirm all values with the trial site)
• People who are able to understand the trial procedures and are willing to sign a written consent form

Who may not be able to join:

• People who have had a significant episode of gastrointestinal (gut) bleeding within the 30 days before entering the trial
• People with a serious heart condition that would make treatment unsafe, such as certain irregular heart rhythms that require medication to control
• People who show signs that their liver is no longer functioning adequately, including fluid build-up in the abdomen, gut bleeding related to liver disease, or confusion caused by liver failure
• People who have a known HIV diagnosis
• People who have previously received an organ transplant
• People who are known or believed to be allergic to the study treatments or any other medicines used as part of the trial
• People who have a known tendency to bleed excessively
• People who have experienced a significant bleeding event (above a certain severity level) within the four weeks before the first dose of the study treatment
• People who have a wound, ulcer, or bone fracture that is not healing properly
• People who have tumours in the brain or central nervous system, including cancer that has spread to the brain
• People who are unlikely to be able to follow the treatment schedule and attend all required follow-up appointments

Important: Always verify eligibility with the trial site directly before applying.